AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO) ≥670 pmol/L
Number of subjects: 4352
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and cTnI together
Number of subjects: 4352
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI
Number of subjects: 4352
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP added to a model adjusted for TIMI risk score incorporating cTnI
Number of subjects: 4352
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO and hs-CRP
Number of subjects: 4352
Study 19649552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Number of subjects: 80
Study 19649552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 80
Study 17526629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 149
Study 17526629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion Sustained Release (SR)
Number of subjects: 149
Study 17526629 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 149
Study 17526629 — intervention group
Group type: COMPARATOR
Intervention: General findings
Number of subjects: 149
Study 17526629 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation influence on alcohol use
Number of subjects: 149
Study 15030818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 15030818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 15030818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12139592 — intervention group
Group type: COMPARATOR
Intervention: N2O/O2‐fentanyl
Number of subjects: 40
Study 12139592 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 40
Study 12139592 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 12139592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 10357331 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 20 mg every 12 h
Number of subjects: 0
Study 10357331 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxycodone 10 mg every 4 h
Number of subjects: 0
Study 10357331 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxycodone 10 mg every 4 h as needed
Number of subjects: 0
Study 7892519 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alcohol intake and nutrient intake
Number of subjects: 282
Study 7892519 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates intake
Number of subjects: 282
Study 7892519 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated lipid intake
Number of subjects: 282
Study 7892519 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption (more than 100 g ethanol per day)
Number of subjects: 282
Study 1974100 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg carvedilol i.v.
Number of subjects: 16
Study 1974100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 333997 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 0.5 mg terbutaline
Number of subjects: 12
Study 333997 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive doses of 0.25 mg terbutaline
Number of subjects: 12
Study 333997 — intervention group
Group type: EXPERIMENTAL
Intervention: Four consecutive doses of 0.125 mg terbutaline
Number of subjects: 12
Study 31180608 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Cerebral Artery (MCA) Doppler evaluation
Number of subjects: 20
Study 31180608 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Artery (UA) Doppler evaluation
Number of subjects: 20
Study 29211735 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed patrol by uniformed, unarmed security agents
Number of subjects: 0
Study 29211735 — intervention group
Group type: COMPARATOR
Intervention: Control stations (no directed patrol)
Number of subjects: 0
Study 24499166 — intervention group
Group type: EXPERIMENTAL
Intervention: Egitromb 300 mg at admission followed by 8 days of 75 mg Egitromb daily (Group A, n = 28)
Number of subjects: 53
Study 24499166 — intervention group
Group type: COMPARATOR
Intervention: Plavix 300 mg at admission followed by 8 days of 75 mg Plavix daily (Group B, n = 25)
Number of subjects: 53
Study 23907506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone-based intervention
Number of subjects: 474
Study 23907506 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 474
Study 22184293 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal normal saline infusion (INSI)
Number of subjects: 158
Study 22184293 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary recruitment maneuver (PRM)
Number of subjects: 158
Study 19336358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation (5 minerals and 10 vitamins at levels approximating the recommended daily allowance)
Number of subjects: 5828
Study 19336358 — intervention group
Group type: COMPARATOR
Intervention: Folic acid plus iron supplementation
Number of subjects: 5828
Study 19336358 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplementation
Number of subjects: 5828
Study 16397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Community agency survey
Number of subjects: 138
Study 16397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Community agency resources and programming
Number of subjects: 138
Study 16397156 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnerships involving community agencies
Number of subjects: 138
Study 15069729 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg/d for 5 days
Number of subjects: 57
Study 15069729 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg, three times a day for 5 days
Number of subjects: 57
Study 11960045 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 82
Study 11960045 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical evacuation
Number of subjects: 82
Study 11960045 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical evacuation
Number of subjects: 82
Study 11960045 — intervention group
Group type: COMPARATOR
Intervention: All methods
Number of subjects: 82
Study 9842842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg/d skin patch and 0.6 mg oral loading dose 60-90 min before surgery)
Number of subjects: 64
Study 9842842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (patches and pills)
Number of subjects: 64
Study 7662197 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons in Zambia
Number of subjects: 7
Study 7662197 — intervention group
Group type: COMPARATOR
Intervention: Surgeons in western hospitals
Number of subjects: 7
Study 2756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg/day
Number of subjects: 132
Study 2756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/day
Number of subjects: 132
Study 2756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 150 mg/day
Number of subjects: 132
Study 2756515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 412646 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate moulded tablet ('Nitrostat')
Number of subjects: 13
Study 412646 — intervention group
Group type: COMPARATOR
Intervention: Generic compressed tablet
Number of subjects: 13
Study 30646205 — intervention group
Group type: EXPERIMENTAL
Intervention: IIDEA treatment (10 sessions)
Number of subjects: 341
Study 30646205 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 341
Study 29364743 — intervention group
Group type: EXPERIMENTAL
Intervention: I-Gel airway (IGA)
Number of subjects: 19
Study 29364743 — intervention group
Group type: COMPARATOR
Intervention: King Laryngotracheal airway (KA)
Number of subjects: 19
Study 27159403 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 193
Study 27159403 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 193
Study 24444287 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intrauterine contraception (IUC) placement post-abortion
Number of subjects: 1500
Study 24444287 — intervention group
Group type: COMPARATOR
Intervention: Delayed intrauterine contraception (IUC) placement four weeks post-abortion
Number of subjects: 1500
Study 22930176 — intervention group
Group type: EXPERIMENTAL
Intervention: MiroCam
Number of subjects: 50
Study 22930176 — intervention group
Group type: COMPARATOR
Intervention: EndoCapsule
Number of subjects: 50
Study 20420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-locked H-plate system with autogeneous cancellous bone (155 trauma patients)
Number of subjects: 485
Study 20420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-locked H-plate system with tricortical autograft (167 patients)
Number of subjects: 485
Study 20420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked cervical plate system with tricortical autograft (73 patients)
Number of subjects: 485
Study 20420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standalone cages filled with autolog cortico-spongiosus bone chips (90 patients)
Number of subjects: 485
Study 18030180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments for chronic diseases
Number of subjects: 192
Study 18030180 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting pill intake
Number of subjects: 192
Study 18030180 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative measure of adherence (adherent patient, yes/no)
Number of subjects: 192
Study 18030180 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of treatment prescribed
Number of subjects: 192
Study 15691301 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 295
Study 15691301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 295
Study 15691301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 295
Study 15691301 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study 12046348 — intervention group
Group type: EXPERIMENTAL
Intervention: SA gene A1A2 polymorphism in women with PIH
Number of subjects: 124
Study 10036952 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week treatment with LPZ 30 mg once daily, AMPC 1500 mg twice daily, CAM 800 mg twice daily
Number of subjects: 106
Study 10036952 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week treatment with LPZ 30 mg once daily, AMPC 1500 mg twice daily, CAM 800 mg twice daily
Number of subjects: 106
Study 7575314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam (TRZ)
Number of subjects: 8
Study 7575314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 8
Study 2109286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin alone
Number of subjects: 72
Study 2109286 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin with pulse methylprednisolone for rejection
Number of subjects: 72
Study 2109286 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisolone
Number of subjects: 72
Study 6989067 — intervention group
Group type: EXPERIMENTAL
Intervention: HRE (isoniazid, rifampicin, ethambutol) for 2 months followed by H2R2 (isoniazid and rifampicin twice weekly) for 4 months
Number of subjects: 530
Study 6989067 — intervention group
Group type: EXPERIMENTAL
Intervention: HRSZ (isoniazid, rifampicin, streptomycin, pyrazinamide) for 2 months followed by 4HRE (isoniazid, rifampicin, ethambutol daily) for 4 months
Number of subjects: 530
Study 6989067 — intervention group
Group type: EXPERIMENTAL
Intervention: H1R1E1 or H2R2 (isoniazid, rifampicin, ethambutol intermittently) for 4 months
Number of subjects: 530
Study 6989067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide included in the initial phase of treatment
Number of subjects: 530
Study 6989067 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimens (6 months)
Number of subjects: 530
Study 31580094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nietos Activos y Saludables intervention (4 weekly sessions)
Number of subjects: 12
Study 27705075 — intervention group
Group type: EXPERIMENTAL
Intervention: Physioball between knees
Number of subjects: 18
Study 27705075 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band around knees
Number of subjects: 18
Study 27705075 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (4 LP sets without intervention)
Number of subjects: 18
Study 27063626 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP) 150mg
Number of subjects: 0
Study 27063626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24241508 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke-specific follow-up care model (5 home visits by a stroke care coordinator over 18 months)
Number of subjects: 117
Study 24241508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 117
Study 21932067 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective family-focused intervention
Number of subjects: 1062
Study 21932067 — intervention group
Group type: COMPARATOR
Intervention: Universal intervention
Number of subjects: 1062
Study 21932067 — intervention group
Group type: COMPARATOR
Intervention: Combination of interventions
Number of subjects: 1062
Study 21932067 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1062
Study 19261962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist's intervention to improve medication adherence
Number of subjects: 0
Study 19261962 — intervention group
Group type: COMPARATOR
Intervention: Prescription refill adherence measurement
Number of subjects: 0
Study 19261962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-point of 80% for defining nonadherence
Number of subjects: 0
Study 17707822 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 56
Study 17707822 — intervention group
Group type: COMPARATOR
Intervention: TVT
Number of subjects: 56
Study 16361729 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxytetracycline hydrochloride (tetracycline)
Number of subjects: 49
Study 16361729 — intervention group
Group type: COMPARATOR
Intervention: Combination of topical tetracycline and oral antibiotics
Number of subjects: 49
Study 12530759 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group receiving suggestive information
Number of subjects: 101
Study 12530759 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 9605061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ergotamine (0.25 mg)
Number of subjects: 15
Study 10160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong social support for not smoking
Number of subjects: 1110
Study 10160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong social support for limiting dietary fat
Number of subjects: 1110
Study 10160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in social support over 12 months
Number of subjects: 1110
Study 10160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline social support
Number of subjects: 1110
Study 10160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support by gender
Number of subjects: 1110
Study 1620417 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 22 hours the night before surgery
Number of subjects: 60
Study 1620417 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg at 22 hours the night before surgery
Number of subjects: 60
Study 1620417 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg at 6 hours on the morning of surgery
Number of subjects: 60
Study 1620417 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients, no drugs)
Number of subjects: 60
Study 6431812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine therapy (100 mg orally every eight hours)
Number of subjects: 20
Study 6431812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30709665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadazolid 250 mg twice daily with vancomycin-matching placebo capsule four times daily for 10 days
Number of subjects: 1263
Study 30709665 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times a day with cadazolid-matching placebo suspension twice daily for 10 days
Number of subjects: 1263
Study 30709665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadazolid 250 mg twice daily
Number of subjects: 1263
Study 30709665 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 125 mg four times a day
Number of subjects: 1263
Study 29523533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (2 500-mg capsules before surgery)
Number of subjects: 486
Study 29523533 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen (1,000 mg/100 mL during surgery)
Number of subjects: 486
Study 29523533 — intervention group
Group type: COMPARATOR
Intervention: Intravenous acetaminophen
Number of subjects: 486
Study 26739997 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 500 µg
Number of subjects: 103
Study 26739997 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 µg
Number of subjects: 103
Study 26739997 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 500/100 µg
Number of subjects: 103
Study 26739997 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 103
Study 26739997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 25129615 — intervention group
Group type: EXPERIMENTAL
Intervention: Set-back suture
Number of subjects: 42
Study 25129615 — intervention group
Group type: COMPARATOR
Intervention: Buried vertical mattress suture (BVMS)
Number of subjects: 42
Study 23544676 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous tones
Number of subjects: 0
Study 23544676 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous tones
Number of subjects: 0
Study 23544676 — intervention group
Group type: COMPARATOR
Intervention: Alternating tones
Number of subjects: 0
Study 20583396 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral sildenafil + 40 microg beraprost
Number of subjects: 50
Study 20583396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18236058 — intervention group
Group type: EXPERIMENTAL
Intervention: Praneem polyherbal pessary
Number of subjects: 100
Study 18236058 — intervention group
Group type: COMPARATOR
Intervention: Ginlac-V pessary
Number of subjects: 100
Study 16770616 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg ornidazole
Number of subjects: 160
Study 16770616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 14553835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuna fish oil
Number of subjects: 173
Study 14553835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 14553835 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid rich sunflower oil
Number of subjects: 173
Study 14553835 — intervention group
Group type: COMPARATOR
Intervention: Evening primrose oil
Number of subjects: 173
Study 14553835 — intervention group
Group type: COMPARATOR
Intervention: Soya bean oil
Number of subjects: 173
Study 14553835 — intervention group
Group type: COMPARATOR
Intervention: Tuna/evening primrose oil mix
Number of subjects: 173
Study 10974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 67
Study 10974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once daily
Number of subjects: 67
Study 10974182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10974182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 67
Study 9393572 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser therapy (ELT) only using a ND‐Yag Laser system (Group I and II)
Number of subjects: 81
Study 9393572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapeutic regime with endocavitary Ir‐192 afterloading following ELT (Group III)
Number of subjects: 81
Study 9393572 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic laser therapy (ELT) only (Group I and II)
Number of subjects: 81
Study 8286230 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% liquor carbonis detergens (LCD) in an emollient base
Number of subjects: 18
Study 8286230 — intervention group
Group type: COMPARATOR
Intervention: Emollient base alone
Number of subjects: 18
Study 2949417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex 500 micrograms/day
Number of subjects: 27
Study 2949417 — intervention group
Group type: COMPARATOR
Intervention: Zoladex 250 micrograms/day
Number of subjects: 27
Study 2949417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex 3.6 mg once-monthly depot
Number of subjects: 27
Study 2949417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (all dosages)
Number of subjects: 27
Study 2949417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 27
Study 29771169 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Number of subjects: 310
Study 25614494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7621
Study 25614494 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7621
Study 24986531 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test (OGTT) and three isocaloric (500 kcal) and isovolaemic (350 ml) liquid meals with varying fat content (2.5g, 10g, 40g)
Number of subjects: 30
Study 24986531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 30
Study 24986531 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT and meals
Number of subjects: 30
Study 24986531 — intervention group
Group type: COMPARATOR
Intervention: Patients with T2DM
Number of subjects: 30
Study 24986531 — intervention group
Group type: COMPARATOR
Intervention: Incretin responses
Number of subjects: 30